Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
Last trade$5.12
Day change-$0.105 (-2.01%)
Day range$5.01 – $5.33
Volume250,395
Market cap$240M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$239.86M
Price / earnings
—
Price / book
0.69×
Price / sales
27.89×
EV / sales
21.77×
EV / EBITDA
-1.56×
Profitability
Earnings per share
-$2.35
Return on assets
-29.32%
Return on equity
-31.12%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
15.51×
Quick ratio
15.51×
Cash ratio
2.77×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$103M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BIOA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$298K
$2.45M
$2.77M
$3.08M
$2.05M
$2.41M
$1.45M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$298K
$2.45M
$2.77M
$3.08M
$2.05M
$2.41M
$1.45M
$0
Selling, general and administrative
$7.48M
$7.42M
$7.74M
$7M
$6.68M
$7.34M
$6.79M
$6.14M
Research and development
$30.23M
$24.37M
$20.41M
$24.5M
$18.51M
$19.84M
$11.11M
$19.23M
Total operating expenses
$37.71M
$31.78M
$28.15M
$31.5M
$25.19M
$27.18M
$17.9M
$25.36M
Operating income
-$37.41M
-$29.33M
-$25.38M
-$28.42M
-$23.14M
-$24.77M
-$16.45M
-$25.36M
Interest expense
$0
-$1K
-$39K
-$92K
-$149K
-$201K
-$255K
-$319K
Income before taxes
-$33.5M
-$26.1M
-$22.25M
-$25.94M
-$20.17M
-$21.56M
-$12.93M
-$21.13M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$33.5M
-$26.1M
-$22.25M
-$25.94M
-$20.17M
-$21.56M
-$12.93M
-$21.13M
Net income attributable to common shareholders
-$33.5M
-$26.1M
-$22.25M
-$25.94M
-$20.17M
-$21.56M
-$12.93M
-$21.13M
EBITDA
-$37.33M
-$29.26M
-$25.31M
-$28.35M
-$23.09M
-$24.71M
-$16.41M
-$25.32M
Basic earnings per share
-$0.73
-$0.58
-$0.52
-$0.72
-$0.56
-$0.60
-$0.36
-$0.59
Diluted earnings per share
-$0.73
-$0.58
-$0.52
-$0.72
-$0.56
-$0.60
-$0.36
-$0.59
Recent news
Company coverage with links to the original publishers.
BioAge Labs (BIOA) reported a quarterly loss of $0.73 per share, missing consensus estimates by 7.35%, with revenues of $0.3 million falling 66.89% short of expectations. The company's stock has declined 55% year-to-date, and it received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. The Medical - Biomedical and Genetics industry ranks in the top 45% of sectors.
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.
BioAge Labs announced the first participant dosing in QUELL-CV, a Phase 2 trial of BGE-102, an oral NLRP3 inhibitor for patients with obesity and elevated inflammation. Phase 1 data showed BGE-102 achieved up to 98% suppression of IL-1β and 86% median hsCRP reductions. The company also plans to initiate QUELL-DME trial in diabetic macular edema in mid-2026. BioAge reported Q2 2026 net loss of $26.1 million with $381.3 million in cash, sufficient to fund operations through 2029.
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. The randomized, double-blind, placebo-controlled trial will enroll approximately 160 participants with obesity and elevated inflammation across three dose levels. Phase 1 results showed BGE-102 achieved median hsCRP reductions of 86% and was well tolerated. Topline data are anticipated in the second half of 2026, with an additional Phase 1b/2a trial in diabetic macular edema planned for mid-2026.
BioAge Labs, a clinical-stage biotechnology company, announced it will participate in the Jefferies Global Healthcare Conference (June 3-4, 2026) and Goldman Sachs Global Healthcare Conference (June 8-10, 2026). Company executives will present and hold one-on-one meetings at both events. BioAge is developing BGE-102, an NLRP3 inhibitor for cardiometabolic diseases, with Phase 2 cardiovascular data expected by end of 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.